Physician profile
Brandon Grady
NPI 1932785342
$3,081.40
in general payments reported to CMS, 2019-2025
35 companies · $620 in 2025
The $620 reported for 2025 was more than what 75% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $672 · 2023: $800 · 2024: $990 · 2025: $620.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,409.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,409.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $662.04 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $429.77 | 2022-2025 | Mounjaro, Trulicity, Zepbound |
| Pfizer INC. | $347.68 | 2023-2025 | |
| Exact Sciences Corporation | $217.90 | 2023-2025 | Cologuard Collection Kit |
| Amgen INC. | $171.87 | 2022-2025 | Evenity, Prolia, Otezla |
| Abbvie INC. | $129.31 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $115.44 | 2024-2025 | Jardiance |
| Glaxosmithkline, LLC. | $110.91 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Dexcom, INC. | $92.64 | 2022-2024 | Dexcom G6 Transmitter |
| Biohaven Pharmaceutical Holding Company LTD. | $78.94 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $72.86 | 2022-2025 | Airsupra, Breztri |
| Aimmune Therapeutics, INC. | $68.42 | 2024-2025 | Zenpep |
| Upsher-Smith Laboratories LLC | $56.13 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $54.23 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $49.32 | 2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $39.88 | 2023 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $36.83 | 2022 | |
| Boston Scientific Corporation | $33.11 | 2024 | Watchman Flx |
| Amneal Pharmaceuticals LLC | $29.27 | 2023 | Unithroid |
| Alexion Pharmaceuticals, INC. | $24.64 | 2025 | Strensiq |
| Phathom Pharmaceuticals, INC. | $20.46 | 2023 | Voquezna |
| Axsome Therapeutics, INC. | $19.59 | 2025 | Auvelity |
| Grifols USA, LLC | $19.24 | 2024 | Prolastin-C Liquid |
| Mayne Pharma Commercial LLC | $19.01 | 2023 | |
| Tolmar, INC. | $18.85 | 2025 | Jatenzo |
| Inspire Medical Systems, INC. | $18.63 | 2024 | Inspire |
| Nestle Healthcare Nutrition INC. | $18.46 | 2023 | |
| Amarin Pharma, INC. | $18.26 | 2022 | |
| Scpharmaceuticals INC. | $17.15 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.15 | 2023 | Trintellix |
| E.R. Squibb & Sons, L.L.C. | $15.47 | 2022 | |
| Sanofi-Aventis U.S. LLC | $15.39 | 2025 | |
| Shield Therapeutics INC | $15.04 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.68 | 2023 | |
| Idorsia Pharmaceuticals US INC | $13.83 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandon Grady listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.